期刊文献+

氯氮平在中国精神分裂症人群的群体药物动力学研究 被引量:9

Population pharmacokinetics research of clozapine in Chinese schizophrenic patients
原文传递
导出
摘要 本研究旨在考察口服氯氮平(clozapine)在中国精神分裂症患者中的群体药物动力学特征,探讨各项动力学参数与人口统计学因素及CYP1A2酶基因多态性的关系,通过建立群体药物动力学模型指导临床个体化给药。研究中采集了临床服用氯氮平的183例精神分裂症患者的626份稳态血样本资料,随机分组为建模组(168例)和外部验证组(15例)。用非线性混合效应模型(NONMEM)程序中的一级评估法(first-order estimation,FO)对建模组的数据进行分析,估算清除率(CL/F)、表观分布容积(V/F)和吸收速率常数(Ka)的群体值,并且定量评价人口统计学指标和CYP1A2酶基因型因素对药物动力学参数的影响。建模中单室一级吸收和消除模型能够较好地拟合数据。最终模型包含了经体表面积归一化的单日剂量(DBSA)和吸烟(SMOK)因素对CL/F的影响。CL/F(非吸烟组)、V/F和Ka的群体典型值分别为28.5 L.h-1(5.05%)、1 290 L(16.7%)和2.26 h-1(fixed),相应的个体间变异分别为42.2%和10.0%。研究发现吸烟组的清除率有所上升。观测值与预测值之间的残留误差SD为45.8μg.L-1。 The goal of this study is to investigate the population pharmacokinetics of oral given clozapine in Chinese schizophrenic patients and to identify possible relationships between population parameters and covariates including demography factors and CYP1A2 genetic polymorphism, so as to create the population pharmacokinetics model to guide individual clinical delivery. Details of drug dosage history, sampling time and concentration of 626 data points from 183 patients were collected retrospectively. The 183 patients were randomly allocated either to the index group (n = 168) or to the validation group (n = 15). Population pharmacokinetic data analysis was performed using the nonlinear mixed-effects model (NONMEM) program on the index group. The values of apparent clearance (CL/F), apparent volume of distribution (V/F) and the constant of absorption rate were estimated. A number of covariates including demographic index, coadministration of other drugs and CYP1A2 genotypes were evaluated statistically for their influence on these parameters. The final population model related clearance with day-dose/BSA (DBSA) and smoke habit (SMOK). Predictive performance of the final model evaluated with the validation group showed insignificant bias between observed and model predicted concentrations. Typical value of CL/F (non-smoking group), V/F and the constant of absorption rate were 28.5 L.h^-1 (5.05%), 1 290 L (16.7%) and 2.26 h^-1 (fixed), inter-patient variability (CV) in CL/F and V/F was 42.2% and 10.0%, respectively. It was observed that the values of CL/F in the two smoking groups were higher than that in the non-smoking group. The residual variability (SD) between observed and model-predicted concentrations was 45.8μg.L^-1.
出处 《药学学报》 CAS CSCD 北大核心 2009年第7期785-792,共8页 Acta Pharmaceutica Sinica
基金 国家自然科学基金资助项目(30770776)
关键词 氯氮平 群体药物动力学 基因多态性 精神分裂症 clozapine population pharmacokinetics genetic polymorphism schizophrenia
  • 相关文献

参考文献7

二级参考文献52

共引文献119

同被引文献43

  • 1贺佳丽,蔡焯基.氯氮平中毒的临床特征和血液灌流疗效的研究[J].中国神经精神疾病杂志,2007,33(4):250-252. 被引量:28
  • 2李焕德,许树梧.HPLC同时测定氯氮平及其代谢物去甲氯氮平血药浓度[J].中国药学杂志,1997,32(8):489-490. 被引量:10
  • 3STAHLSM.精神药理学精要:处方指南[M].于欣,司天梅,译.2版.北京:北京大学医学出版社.2009:441-446.
  • 4HICKS DR, WOLANIUK D, RUSSELL A, et al. A high- performance liquid chromatographic method for the simultaneous determination of venlafaxine and O- desmethylvenlafaxine in biological fluids[J]. Ther Drug Monit, 1994, 16 (1): 100-107.
  • 5HOMERO de SOUZA FILHO J, BONIFACIO FN, BEDOR DC,et al. Relative bioavailability of two formulations of venlafaxine extended- release 75- mg capsules in healthy brazilian male volunteers : A single - dose, randomized - sequence, open - label, two-period crossover study in the fasting and fed states[J]. Clin Ther, 2012, 32(12): 2088-2096.
  • 6FUKUDA T, NISHIDA Y, ZHOU Q, et al, The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmaco- kinetics in a Japanese population[J]. Eur J Pharmacol, 2000, 56 (2) : 175-180.
  • 7冯婉玉.盐酸文拉法辛及其代谢物O-去甲文拉法辛在健康志愿者体内的药代动力学及生物等效性研究[D].沈阳:中国医科大学,2010:29-42.
  • 8SHARGELL,吴幼玲,余炳灼.国外药学专著译丛:应用生物药剂学与药物动力学[M].李安良,吴艳芬,主译.5版.北京:化学工业出版社,2006:106-121.
  • 9孙丽丽,司天梅,刘薏,杨琴,翟所迪,卢炜.用NONMEM法建立西酞普兰群体药代动力学模型[J].中国临床药理学杂志,2008,24(2):151-155. 被引量:4
  • 10张剑萍,郭澄.生物样品分析中的方法学验证[J].中国药房,2008,19(31):2469-2471. 被引量:22

引证文献9

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部